Endocrine reviews

Links Between Glucagon-like Peptide-1 Treatments and Thyroid Cancer: Summary of Lab and Human Studies

Updated

Abstract

Preclinical rodent studies showed a dose-dependent increase in thyroid C-cell hyperplasia and neoplasia with Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs).

  • The United States Federal Drug Administration requires a boxed warning against GLP-1RAs for those with a personal or family history of medullary thyroid carcinoma (MTC).
  • Primate studies and clinical trials did not demonstrate C-cell stimulation, raising doubts about the relevance of rodent findings to humans.
  • Rodents are known to have a higher rate of spontaneous thyroid C-cell tumors and possess different pathways for MTC development compared to humans.
  • Most meta-analyses report no clear association between GLP-1RA use and thyroid cancer, though pharmacovigilance studies suggest a possible signal of concern.
  • Thyroid cancer incidence trends in the U.S. since 2005 indicate an early increase likely due to overdiagnosis, with a decreasing proportion of MTC cases.
  • The majority of data does not support a causative relationship between GLP-1RA use and MTC or papillary thyroid carcinoma (PTC).

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free